| __timestamp | BioCryst Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 520990000000 |
| Thursday, January 1, 2015 | 1896000 | 535405000000 |
| Friday, January 1, 2016 | 2699000 | 558755000000 |
| Sunday, January 1, 2017 | 1702000 | 495921000000 |
| Monday, January 1, 2018 | 471000 | 659690000000 |
| Tuesday, January 1, 2019 | 4101000 | 1089764000000 |
| Wednesday, January 1, 2020 | 1676000 | 994308000000 |
| Friday, January 1, 2021 | 7264000 | 1106846000000 |
| Saturday, January 1, 2022 | 6594000 | 1244072000000 |
| Sunday, January 1, 2023 | 4661000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This analysis compares the cost of revenue trends for Takeda Pharmaceutical Company Limited and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Takeda, a global leader, consistently shows a robust cost of revenue, peaking at approximately 1.43 trillion in 2023, reflecting a 174% increase since 2014. In contrast, BioCryst, a smaller player, exhibits more volatility, with costs fluctuating between 122,000 and 7.26 million over the same period. Notably, BioCryst's costs surged by over 5,800% from 2014 to 2021, highlighting its aggressive growth strategy. However, missing data for 2024 suggests potential reporting gaps. This comparison underscores the diverse financial strategies within the pharmaceutical sector, where scale and innovation drive cost structures differently.
Cost of Revenue Trends: Sanofi vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Cytokinetics, Incorporated
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Annual Revenue Comparison: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Takeda Pharmaceutical Company Limited or BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Vericel Corporation vs BioCryst Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.